Adamis Pharmaceuticals (NASDAQ:ADMP) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Adamis Pharmaceuticals Stock Down 0.1 %

Shares of NASDAQ:ADMP opened at $0.20 on Friday. Adamis Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $0.73. The stock’s 50 day moving average is $0.18 and its 200-day moving average is $0.24.

Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) last issued its earnings results on Monday, November 14th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter. The firm had revenue of $1.51 million during the quarter.

Institutional Investors Weigh In On Adamis Pharmaceuticals

A hedge fund recently raised its stake in Adamis Pharmaceuticals stock. State Street Corp increased its stake in shares of Adamis Pharmaceuticals Co. (NASDAQ:ADMP – Get Rating) by 13.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 475,373 shares of the specialty pharmaceutical company’s stock after buying an additional 55,168 shares during the quarter. State Street Corp owned 0.32% of Adamis Pharmaceuticals worth $271,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.57% of the company’s stock.

About Adamis Pharmaceuticals

(Get Rating)

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets.